Gastric Ulcer | Nexium Capsules LDA Specific Clinical Experience Investigation

Gastric Ulcer research study

What is the primary objective of this study?

The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Who is eligible to participate?

Exclusion Criteria: - Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy). - Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Gastric Ulcer

Duodenal Ulcer

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.


Study Status


Start Date: January 1, 2013

Completed Date: March 9, 2017


Type: Observational


Primary Outcome: Adverse events incidence

Secondary Outcome: Non-recurrence rate of peptic ulcer

Study sponsors, principal investigator, and references

Principal Investigator: Shigeru Yoshida, MD

Lead Sponsor: AstraZeneca


More information:

Discuss Nexium